A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2018
At a glance
- Drugs GBR 830 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 16 Apr 2018 According to a Glenmark Pharmaceuticals media release, enrollment is expected to begin in June 2018.
- 16 Apr 2018 Status changed from planning to recruiting, according to a Glenmark Pharmaceuticals media release.
- 04 Aug 2017 New trial record